Psoriasis, a multifactorial inflammatory condition, has prompted a growing interest in RNA-based therapies, particularly siRNA and miRNA approaches targeting STAT3, keratin 17, and TNF-α pathways, which aim to normalize keratinocyte behavior, suppress inflammation, and modulate angiogenesis. This evidence concerns the gene STAT3 and psoriasis.